- Home
- KZIA vs GSIW Comparison
KZIA vs GSIW Comparison
Compare KZIA & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KZIA | GSIW |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | Australia | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 24.2M |
| IPO Year | 2002 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KZIA | GSIW |
|---|---|---|
| Price | $10.95 | $14.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | ★ 293.3K | 50.5K |
| Earning Date | 06-04-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $0.05 |
| 52 Week High | $17.40 | $38.55 |
Technical Indicators
Market Signals| Indicator | KZIA | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 35.49 | 34.65 |
| Support Level | $5.15 | $13.46 |
| Resistance Level | $10.49 | $18.03 |
| Average True Range (ATR) | 1.15 | 1.71 |
| MACD | -0.32 | 0.11 |
| Stochastic Oscillator | 2.15 | 28.28 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About GSIW Garden Stage Limited
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.